These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28236560)

  • 1. The dynamics of contract plasma fractionation.
    Farrugia A; Scaramuccia D
    Biologicals; 2017 Mar; 46():159-167. PubMed ID: 28236560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
    Cheraghali AM; Aboofazeli R
    Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern plasma fractionation.
    Burnouf T
    Transfus Med Rev; 2007 Apr; 21(2):101-17. PubMed ID: 17397761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generating pathways to domestically sourced plasma-derived medicinal products: Report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion.
    Farrugia A; Perry R; Rossi F; von Bonsdorff L; Bowie G; Faber JC; Omarjee JH; Epstein J; White J
    Vox Sang; 2024 Jun; ():. PubMed ID: 38925641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasma fractionation in the world: current status].
    Burnouf T
    Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience.
    Cheraghali AM; Abolghasemi H
    Haemophilia; 2009 Mar; 15(2):487-93. PubMed ID: 19347989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stepwise access to safe plasma proteins in resource-constrained countries: Local production and pathways to fractionation-Report of an International Society of Blood Transfusion Workshop.
    Burnouf T; Epstein J; Faber JC; Smid M
    Vox Sang; 2022 Jun; 117(6):789-795. PubMed ID: 35262936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma is a strategic resource.
    Strengers PF; Klein HG
    Transfusion; 2016 Dec; 56(12):3133-3137. PubMed ID: 27861951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Report on notifications pursuant to Section 21 German Transfusion Act for 2007].
    Henseler O; Heiden M; Haschberger B; Hesse J; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jul; 52(7):715-31. PubMed ID: 19572110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of Iran national plasma contract fractionation program.
    Cheraghali AM
    Daru; 2012 Oct; 20(1):63. PubMed ID: 23351278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What can be learned in the snake antivenom field from the developments in human plasma derived products?
    Burnouf T
    Toxicon; 2018 May; 146():77-86. PubMed ID: 29621528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Norwegian Plasma Fractionation Project--a 12 year clinical and economic success story.
    Flesland O; Seghatchian J; Solheim BG
    Transfus Apher Sci; 2003 Feb; 28(1):93-100. PubMed ID: 12620274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ethics of Paid Plasma Donation: A Plea for Patient Centeredness.
    Farrugia A; Penrod J; Bult JM
    HEC Forum; 2015 Dec; 27(4):417-29. PubMed ID: 25234254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low- and middle-income countries.
    Burnouf T; Epstein J; Faber JC; Smid WM;
    Vox Sang; 2024 Feb; 119(2):102-109. PubMed ID: 37872819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma for fractionation in a public setting: cost analysis from the perspective of the third-party payer.
    Eandi M; Gandini G; Povero M; Zaniolo O; Pradelli L; Aprili G
    Blood Transfus; 2015 Jan; 13(1):37-45. PubMed ID: 25636129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. “Go no Go” in plasma fractionation in the world’s emerging economies: still a question asked 70 years after the COHN process was developed!
    Burnouf T; Seghatchian J
    Transfus Apher Sci; 2014 Oct; 51(2):113-9. PubMed ID: 25457750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
    Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highlights of PBTI Coimbra Conference on PRT of Plasma & Current Opinions on Pathogen Reduction Treatment of Blood Components.
    de Sousa G; Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):228-32. PubMed ID: 25770045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma fractionation in blood transfusion service.
    Haskó F; Salamon M; Bartha K; Dobó P
    Dev Biol Stand; 1987; 67():39-48. PubMed ID: 3111912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Product delivery in the developing world: options, opportunities and threats.
    Farrugia A
    Haemophilia; 2004 Oct; 10 Suppl 4():77-82. PubMed ID: 15479376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.